Compliance and Regulatory Statement
Clinical Governance & Regulatory Framework
Nūūtro operates under a rigorous governance structure designed to uphold patient safety and legal transparency. Our clinical practice is aligned with the professional standards set by the General Medical Council (GMC).
1. Legal Status of Therapeutic Compounds
In the United Kingdom, many advanced peptide therapies are classified as unlicensed medicinal products (often referred to as “Specials”) or Prescription-Only Medicines (POMs).
Statutory Compliance: We strictly follow MHRA Guidance Note 14, which governs the supply of unlicensed medicinal products for individual patient use.
Clinical Justification: These compounds are only recommended where a clinician determines that a client’s specific needs cannot be met by an equivalent MHRA-licensed product.
Non-Commercial Provision: We do not maintain a “shop” or “pharmacy” for public purchase. All therapies are dispensed solely as part of a bespoke, clinician-led plan.
2. Advertising and Public Communication
Nūūtro adheres to the UK Code of Non-broadcast Advertising and Direct & Promotional Marketing (CAP Code) and the Human Medicines Regulations 2012.
Prohibition of Public Promotion: We do not advertise POMs or unlicensed medicines to the general public.
Educational Intent: Information provided on this website is intended for scientific literacy and educational awareness. It does not constitute a recommendation for any specific medication.
Factual Accuracy: All health-related claims are based on emerging peer-reviewed literature and are qualified as “investigational” or “research-led” where appropriate.
3. Safety, Monitoring, and Pharmacovigilance
Client welfare is the cornerstone of our clinical model. We maintain a high-integrity safety net for every individual under our care.
Diagnostic Integrity: No protocol is initiated without a comprehensive evaluation and a review of medical history.
Informed Consent: We ensure patients receive clear, jargon-free disclosures regarding the nature of their treatment, particularly regarding the use of “unlicensed” products, before any intervention begins.
Professional Disclaimer
The content provided by Nūūtro is for informational purposes only and does not serve as a substitute for professional medical diagnosis or advice. We do not claim to “cure” or “treat” specific diseases through public-facing content. All medical decisions and therapeutic interventions occur exclusively within the privacy of a formal consultation with a registered healthcare professional.
By partaking in Peptide Therapy with Nūūtro, you approve of the following:
1. Understanding “Unlicensed” Medicinal Products
I understand that some of the peptide therapies or compounds discussed by Nūūtro may be classified as unlicensed medicinal products in the United Kingdom.
I acknowledge that while these substances are manufactured to Good Manufacturing Practice (GMP) standards, they may not hold a UK Marketing Authorisation (a “license”) for the specific condition being treated.
I understand and have researched in-depth why an unlicensed product is appropriate for my care over a licensed alternative, hence I am perusing peptide therapies.
2. Clinical Rationale & Emerging Research
I understand that peptide therapy is an emerging field of regenerative medicine.
I have been informed that while there is peer-reviewed evidence supporting the use of these peptides, some applications are based on emerging research and clinical observation rather than long-term, large-scale UK clinical trials.
I acknowledge that results are individualized and not guaranteed.
3. Risks, Side Effects, and Pharmacovigilance
I have been made aware of the potential risks and side effects associated with my specific protocol, which may include but are not limited to:
Localized reactions (redness, bruising, or swelling at the injection site).
Systematic effects (to be detailed by the clinician during consultation).
Reporting: I agree to immediately notify the clinic of any adverse reactions. I understand that Nūūtro may report significant side effects to the MHRA Yellow Card Scheme as part of their commitment to patient safety.
4. Patient Responsibilities
Accuracy: I confirm that I have provided a full and accurate medical history, including all current medications and supplements.
Administration: I agree to use the prescribed protocol strictly as directed by the clinician and will not alter the dosage or frequency without prior consultation.
Monitoring: I understand that monitoring are mandatory requirements for continuing my treatment.